Literature DB >> 18760239

Role of oestrogen in the development of joint symptoms?

Ai Lyn Tan, Paul Emery.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18760239     DOI： 10.1016/S1470-2045(08)70217-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio.

Authors:  Peter Blaha; Ruth Exner; Andrea Dal Borgo; Sinda Bigenzahn; Peter Panhofer; Otto Riedl; Sebastian Schoppmann; Thomas Bachleitner-Hofmann; Emanuel Sporn; Ursula Pluschnig; Florian Fitzal; Guenther Steger; Raimund Jakesz; Peter Dubsky; Michael Gnant
Journal:  Breast Care (Basel)       Date:  2009-06-23       Impact factor: 2.860

2.  The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.

Authors:  Miyuki Kanematsu; Masami Morimoto; Junko Honda; Taeko Nagao; Misako Nakagawa; Masako Takahashi; Akira Tangoku; Mitsunori Sasa
Journal:  BMC Cancer       Date:  2011-10-10       Impact factor: 4.430

3.  Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol.

Authors:  Junko Honda; Miyuki Kanematsu; Misako Nakagawa; Masako Takahashi; Taeko Nagao; Akira Tangoku; Mitsunori Sasa
Journal:  Int J Surg Oncol       Date:  2011-05-26

4.  Rapid Anti-Inflammatory Effects of Gonadotropin-Releasing Hormone Antagonism in Rheumatoid Arthritis Patients with High Gonadotropin Levels in the AGRA Trial.

Authors:  Anita Kåss; Ivana Hollan; Morten Wang Fagerland; Hans Christian Gulseth; Peter Abusdal Torjesen; Øystein Torleiv Førre
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

5.  Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options.

Authors:  Janine M Lombard; Nicholas Zdenkowski; Kathy Wells; Corinna Beckmore; Linda Reaby; John F Forbes; Jacquie Chirgwin
Journal:  Support Care Cancer       Date:  2015-11-10       Impact factor: 3.359

6.  Short-term treatment with a gonadotropin-releasing hormone antagonist, cetrorelix, in rheumatoid arthritis (AGRA): a randomized, double-blind, placebo-controlled study.

Authors:  A S Kåss; O T Førre; M W Fagerland; H C Gulseth; P A Torjesen; I Hollan
Journal:  Scand J Rheumatol       Date:  2013-11-01       Impact factor: 3.641
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.